Patient-monitoring Masimo nets CE mark for noninvasive ‘supersensor’

CE mark showing construction lines
The Rainbow Super DCI-mini sensor reduces the need for multiple sensors to measure parameters, such as oxygen saturation and carboxyhemoglobin levels, in the blood.

Masimo has earned a CE mark for a reusable finger sensor that noninvasively measures a range of physiological parameters at the same time. This reduces the need to use multiple sensors in patient monitoring.

The reusable Rainbow Super DCI-mini sensor may be used to spot-check patients weighing 3 kg or more. It can be applied to an adult’s or child’s finger, and to an infant’s finger, thumb or great toe.

In addition to measuring oxygen saturation (SpO2), it also measures total hemoblogin (SpHb), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and arterial oxygen saturation (SpO2), the company said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Mindray Medical shells out $25M to settle pulse oximeter patent battle with Masimo

Monitoring carboxyhemoglobin can help healthcare staff identify heightened carbon monoxide levels that may otherwise be missed in frontline settings, such as emergency care, the company said. Watching a patient’s methemoglobin—a form of hemoglobin that cannot bind oxygen—is useful in settings, such as the operating room, where drugs are used that can cause methemoglobinemia

“Since the invention of rainbow technology, we have been wanting our customers to be able to measure SpCO, SpMet, SpHb and SpO2 simultaneously. Now they can,” said Masimo CEO Joe Kiani. “In addition, we have been pursuing a spot-check sensor that fits all patients across the age spectrum. We believe the rainbow Super DCI-mini sensor will be especially valuable for use in triage and emergency care situations."


Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.